A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has ...
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The allogenic cell therapy achieved all primary and ...
-- VAX-31 is Designed to Provide Coverage for Approximately 95% of Invasive Pneumococcal Disease Circulating in the U.S. Adult Population -- About the VAX-31 Phase 1/2 StudyThe VAX-31 Phase 1/2 ...
REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results